Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Unaudited)

v3.5.0.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 31,293 $ 97,428
Short-term investments 81,908 102,791
Accounts receivable 11,779 6,170
Note receivable from Viking Therapeutics 4,767 4,782
Inventory 1,750 1,633
Other current assets 1,562 1,908
Total current assets 133,059 214,712
Deferred income taxes 129,777 189,083
Investment in Viking Therapeutics 28,118 29,728
Intangible assets, net 212,823 48,347
Goodwill 72,997 12,238
Commercial license rights 8,546 8,554
Property and equipment, net 567 372
Other assets 70 27
Total assets 585,957 503,061
Current liabilities:    
Accounts payable 2,688 4,083
Accrued liabilities 3,669 5,397
Current contingent liabilities 5,285 10,414
Current lease exit obligations 577 934
Other current liabilities 21 8
Total current liabilities 12,240 222,821
Long-term debt, net 204,653 201,985
Long-term contingent liabilities 4,022 3,033
Other long-term liabilities 446 297
Total liabilities 221,361 226,151
Commitments and Contingencies
Stockholders' equity:    
Common stock, $0.001 par value; 33,333,333 shares authorized; 20,815,636 and 19,949,012 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively 21 20
Additional paid-in capital 783,890 661,850
Accumulated other comprehensive income 3,568 4,903
Accumulated deficit (422,883) (429,491)
Total stockholders' equity attributable to Ligand Pharmaceuticals 364,596 237,282
Total liabilities and stockholders' equity $ 585,957 $ 503,061